I would like to clarify things. To the best of my

New Post Public Reply Private Reply Replies (1) Message Board
wrmckay
1,202
I would like to clarify things. To the best of my recollection, I have spoken to Carson (thesmalls) twice. Once was in September of 2016 and once in December. In the first instance, he was blocked by IR or Muse and wanted my help to get him unblocked. I offered to help and asked him to refrain from posting or communicating for a few days while I attempted to get him unblocked. Within a few hours of our conversation he was posting again, making my task more difficult. The second conversation was of a similar nature and again I asked him to be patient and again he was not. On both occasions he was full of bluster, telling me how the company should be run, how many shares he had, how he was a long-term investor and very successful, etc. I have an obligation to listen to all shareholders, so I did listen to him.

One thing should be made clear. Carson does not have an inside track regarding information coming from me. The communication with him has been minimal at best. It was clear in talking to him that he had an agenda, much like Spuds and that nothing I said would change his mind or his objective, which in my opinion is to simply be right, even when he may not be. I find it interesting when people like Carson or Spuds are cordial in one-on-one communications, but rant and spread vitriol to the general public. In private they invite me to have a beer with them and in public say that I should be put in jail.

Carson has received no information regarding revenue projections because I haven't given them out. He has requested them as naseam, I'm sure only for the purpose to say they are wrong, if they aren't met. The fact is that at this point it's difficult to make projections, because we don't know how the e-bikes will be received, nor the trikes in Africa. We have a feel for how they will do, but not hard numbers. However, we don't think that first year sales of 20,000 e-bikes is unreasonable, which will put revenue at $14,000,000. For trikes, we don't think first year sales of 10,000 units is unreasonable, which would add another $8,000,000 to revenue. This coupled with EIA and hopefully bearings and SLAs would enhance revenue.

One thing is certain. We do have revenue for this year and expect a lot more. We view this as a breakout year. At the same time folks bash the company for many reasons. Some are personal, some are ego and some are to get people to sell so they can trade. So when IR or Muse says things like hold thru the no bid situation, that means that Muse believes big things will happen, while Carson and others believe it will go to no bid. Muse is saying that people should hold their shares, even if they think it will go to no bid, because there is light at the end of the tunnel and big things will happen.

I am very confident that big things ARE happening. We are preparing the first shipment of e-bikes to the States and are also preparing the first trike shipment. Both sets of vehicles have been paid for and will go to distributors who are already creating strong market interest.

I've not come out and said these things before, but I completely recommend that people hold their shares. Big things are happening and we will have a breakout this year. People have been very patient, but this patience is about to pay off. I'm thankful for the words of support from most people and feel compassion for the bashers. Life is too short to go around bitter and unhappy. Enjoy the short time we all have. TPAC will be successful and it will show to those who can wait.

Trans-Pacific Aerospace (TPAC) Stock Research Links

TPAC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 50

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 84

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

Equitage Ventures Launches $47.3M Fund for Senior Care Tech

Updated Category News Views 329

Equitage Ventures Launches Significant Investment Fund Equitage Ventures, an early-stage venture capital firm dedicated to AgeTech, has announced the successful final closing of a substantial $47.3 million investment fund. This fund is designed to provide critical capital, distribution resources, and strategic guidance to innovative entrepreneurs who aim to tackle the...

Continue Reading
Understanding Market Trends: Insights into Chevron Corp's Performance

Updated Category News Views 171

Chevron Corp Market Sentiment Analysis Chevron Corp (NYSE: CVX) has experienced a noteworthy decline in its short interest as a percentage of float, showing a 10.26% decrease since its previous report. Currently, there are approximately 14.02 million shares sold short, which accounts for 0.7% of all shares available for trading. Given the trading volume, it is estimated...

Continue Reading
Establishment of Blakely McCrory Hope Fund at Moody Gardens

Updated Category News Views 200

Introducing the Blakely McCrory Hope Fund Moody Gardens is proud to announce a special initiative to honor the memory of a young girl who captured the hearts of many: the Blakely McCrory Hope Fund. This fund has been established in loving memory of 8-year-old Blakely McCrory, who lost her life in a tragic flooding incident that occurred during the summer months....

Continue Reading
Star-Studded Table Read of 'It's a Wonderful Life' Event

Updated Category News Views 221

Exciting Holiday Table Read for a Worthy Cause The Ed Asner Family Center is pulling out all the stops this holiday season with an exciting virtual table read of the beloved classic, "It's a Wonderful Life." Scheduled for December 14 at 5 PM PST, this event promises to spread joy while supporting individuals and families with special needs. Star-Studded Cast Comes...

Continue Reading
Transforming $100 Into Over $1700 with Monolithic Power Systems

Updated Category News Views 145

Understanding the Growth of Monolithic Power Systems Monolithic Power Systems (NASDAQ: MPWR) has showcased impressive financial performance over the past decade, outperforming many market benchmarks. With an impressive annualized growth rate of 19.88%, it has attracted the attention of savvy investors. The Power of Compounded Returns Imagine investing $100 in MPWR stock...

Continue Reading